Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ:NAGE) announced that senior management will present at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026, at The Westin Times Square in New York.
CEO Rob Fried will present from 2:40–3:15 PM ET, with a livestream available via the conference host’s website. CFO Ozan Pamir will attend for one-on-one investor meetings.
Niagen Bioscience (NASDAQ:NAGE) renamed the ChromaDex External Research Program to the Niagen Research Program, aligning it with the company’s branding and NAD+ focus. The program has enabled 300+ collaborations and 45+ published human clinical studies using Niagen, and currently supports over 175 active or developing studies.
Niagen Bioscience (NASDAQ: NAGE) said senior leaders will attend two investor conferences in May 2026: the 31st Annual Sohn Investment Conference on May 12 at Jazz at Lincoln Center and the 4th Annual Benchmark Consumer One-On-One Conference on May 19 at the New York Athletic Club. Management participants include CEO Rob Fried and CFO Ozan Pamir.
Meetings include an Emerging Company Pavilion showcase and one-on-one sessions. To schedule a meeting, contact your conference representative or email Niagen@KCSA.com. Visit www.niagenbioscience.com for additional company information.
Summary not available.
Niagen Bioscience (NASDAQ: NAGE) launched Niagen Plus, a clinician-directed telehealth platform and prescription-only Niagen At-Home Injection Kit for subcutaneous administration in eligible U.S. patients. The kit is dispensed by a licensed 503A pharmacy, manufactured to cGMP standards, and follows clinician-prescribed 50 mg or 100 mg dosing protocols.
A company clinical safety trial reported no significant adverse effects at 50 mg/mL and 100 mg/mL; preclinical models suggest injectable delivery may increase tissue availability.
Niagen Bioscience (NASDAQ: NAGE) partnered with Olympia Pharmaceuticals, a U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen Plus intravenous and injectable products.
The partnership broadens the company’s 503B network beyond Wells Pharma, cites a newly granted patent for IV/injectable Niagen methods, and notes Olympia’s licensing across 49 states and cGMP operations.
Niagen Bioscience (NASDAQ: NAGE) will report first quarter 2026 financial results after market close on Wednesday, May 6, 2026, and host a conference call and live webcast the same day at 4:30 p.m. ET (1:30 p.m. PT).
The webcast will be available on the company website, with replay accessible from 7:30 p.m. ET on May 6, 2026, through 11:59 p.m. ET on May 6, 2027. Toll-free dial-in: +1 (833) 461-5787; Conference ID: 828848803.
Niagen Bioscience (NASDAQ: NAGE) announced that Nicotinamide Riboside Chloride (NRCl), the patented form in Niagen®, now has a published USP dietary supplement monograph.
The monograph, produced with six years of collaboration, defines identity, assay, impurity, microbial, packaging and storage requirements and is expected to be codified and enforced in October 2026.
Niagen Bioscience (NASDAQ:NAGE) announced a first-of-its-kind partnership with OneSpaWorld (NASDAQ:OSW) to offer pharmaceutical-grade Niagen IV at more than 80 Medi-Spa clinics aboard high-end cruise ships, expanding Niagen Plus reach to on-vacation consumers.
The Niagen IV aqueous formulation is stated to enable 75% shorter infusion times, a faster rise in NAD+ blood levels, a newly granted patent for IV/injectable methods of use, and 500 mg product availability via a U.S. FDA-registered outsourcing facility.
Niagen Bioscience (NASDAQ: NAGE) increased its share repurchase program authorization from $10 million to $20 million, with approximately $2.6 million repurchased through March 17, 2026. The program runs through October 31, 2027 unless earlier modified, suspended, or terminated.
Repurchases may be executed opportunistically via open market or negotiated transactions and do not obligate the company to buy any specific amount. Additional repurchase details will appear in the company’s periodic SEC reports.